Sana Biotechnology (NASDAQ:SANA) Trading 5.7% Higher After Analyst Upgrade

Sana Biotechnology, Inc. (NASDAQ:SANA)’s stock price traded up 5.7% during trading on Tuesday after TD Cowen upgraded the stock to a strong-buy rating. The company traded as high as $4.03 and last traded at $3.9940. Approximately 217,738 shares were traded during mid-day trading, a decline of 93% from the average daily volume of 3,107,267 shares. The stock had previously closed at $3.78.

A number of other analysts have also issued reports on the stock. Weiss Ratings upgraded shares of Sana Biotechnology from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, July 23rd. Bank of America cut their price target on Sana Biotechnology from $7.00 to $6.00 and set a “buy” rating for the company in a report on Friday, August 14th. Rodman & Renshaw assumed coverage on Sana Biotechnology in a research note on Monday, May 11th. They set a “buy” rating and a $16.00 price target on the stock. Finally, Wall Street Zen downgraded Sana Biotechnology from a “hold” rating to a “sell” rating in a research report on Monday, July 20th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $9.33.

Institutional Trading of Sana Biotechnology

Hedge funds have recently made changes to their positions in the company. California State Teachers Retirement System grew its position in shares of Sana Biotechnology by 287.8% during the second quarter. California State Teachers Retirement System now owns 634,304 shares of the company’s stock worth $2,214,000 after acquiring an additional 470,745 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of Sana Biotechnology by 22.8% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 284,472 shares of the company’s stock valued at $993,000 after buying an additional 52,766 shares during the period. Hsbc Holdings PLC lifted its holdings in Sana Biotechnology by 55.1% in the 2nd quarter. Hsbc Holdings PLC now owns 111,959 shares of the company’s stock valued at $392,000 after acquiring an additional 39,765 shares during the last quarter. Corient Private Wealth LP bought a new stake in Sana Biotechnology during the second quarter worth approximately $2,192,000. Finally, Bank of America Corp DE bought a new stake in shares of Sana Biotechnology during the 2nd quarter worth $20,062,000. Hedge funds and other institutional investors own 88.23% of the company’s stock.

Sana Biotechnology Trading Up 6.5%

The stock has a 50-day moving average of $3.49 and a two-hundred day moving average of $3.41. The firm has a market cap of $1.20 billion, a price-to-earnings ratio of -5.29 and a beta of 2.16.

Sana Biotechnology (NASDAQ:SANA) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.02. Sell-side analysts expect that Sana Biotechnology, Inc. will post -0.72 EPS for the current fiscal year.

Sana Biotechnology Company Profile

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.